Chromophobe renal cell carcinoma: Emerging vulnerabilities as a promise for a new therapeutic landscape

Area of Science:

• Oncology
• Renal Cell Carcinoma Subtypes
• Cancer Biology

Background:

• Chromophobe renal cell carcinoma (ChRCC) is a rare, distinct subtype of renal cell carcinoma.
• ChRCC is characterized by low tumor mutational burden, mitochondrial abnormalities, and unique metabolic dependencies.
• Historically, ChRCC has lacked tailored therapeutic options due to its classification and trial exclusion.

Purpose of the Study:

• To review emerging clinical trial data on immune checkpoint and tyrosine kinase inhibitors in ChRCC.
• To highlight ChRCC-specific therapeutic vulnerabilities and promising novel treatment strategies.
• To emphasize the need for biology-informed, inclusive clinical trials for ChRCC patients.

Main Methods:

• Review of recent clinical trial data and scientific literature.
• Analysis of ChRCC-specific biological features and potential therapeutic targets.
• Identification of emerging therapeutic avenues including ferroptosis induction, KIT-targeting ADCs, and NK cell therapy.

Main Results:

• Immune checkpoint and tyrosine kinase inhibitors show variable efficacy in ChRCC.
• Emerging data points to distinct therapeutic vulnerabilities in ChRCC.
• Three promising avenues include ferroptosis induction, KIT-targeting antibody-drug conjugates, and natural killer adoptive cell therapy.

Conclusions:

• ChRCC biology necessitates tailored therapeutic approaches beyond traditional non-clear cell classifications.
• Targeting ChRCC-specific vulnerabilities offers promising new treatment strategies.
• Multiprofessional collaboration and biology-informed trials are crucial for advancing ChRCC patient outcomes.